Table 1.
Meta-analysis of the HIF-1α 1772 C/T polymorphism and cancer association.
| Genetic contrasts | Group and subgroups under analysis |
Studies (n) | Q test P value |
Model seclected |
OR (95% CI) |
P |
|---|---|---|---|---|---|---|
| T versus C | Overall | 18 | <0.00001 | Random | 1.29 (1.01, 1.65) | 0.04 |
| Overall in HWE | 13 | <0.00001 | Random | 1.39 (1.02, 1.90) | 0.04 | |
| Caucasian | 11 | <0.00001 | Random | 1.33 (0.90, 1.97) | 0.15 | |
| Caucasian in HWE | 7 | <0.00001 | Random | 1.69 (0.94, 3.04) | 0.08 | |
| East Asian | 5 | 0.16 | Fixed | 1.05 (0.84, 1.30) | 0.69 | |
| Female* | 7 | <0.00001 | Random | 1.39 (0.83, 2.35) | 0.21 | |
| Female in HWE* | 6 | <0.00001 | Random | 1.48 (0.81, 2.71) | 0.20 | |
| Male (prostate cancer)** | 4 | <0.0001 | Random | 1.78 (1.07, 2.94) | 0.03 | |
| Male (prostate cancer) in HWE** |
3 | <0.0001 | Random | 1.68 (0.94, 3.02) | 0.08 | |
| Breast cancer | 3 | 0.12 | Fixed | 0.99 (0.79, 1.23) | 0.90 | |
| Colorectal cancer | 2 | 0.02 | Random | 0.26 (0.01, 6.38) | 0.41 | |
| TT versus (CT+CC) | Overall | 18 | 0.02 | Random | 2.18 (1.32, 3.62) | 0.003 |
| Overall in HWE | 13 | 0.002 | Random | 2.87 (1.14, 7.26) | 0.03 | |
| Caucasian | 11 | 0.02 | Random | 2.40 (1.26, 4.59) | 0.008 | |
| Caucasian in HWE | 7 | 0.01 | Random | 3.35 (1.01, 11.11) | 0.05 | |
| East Asian | 5 | 0.76 | Fixed | 5.31 (0.91, 30.83) | 0.06 | |
| Female* | 7 | 0.02 | Random | 3.60 (1.17, 11.11) | 0.03 | |
| Female in HWE* | 6 | 0.01 | Random | 3.88 (0.94, 16.01) | 0.06 | |
| Male (prostate cancer)** | 4 | 0.1 | Fixed | 1.53 (0.90, 2.60) | 0.11 | |
| Male (prostate cancer) in HWE** |
3 | 0.04 | Random | 1.78 (0.41, 7.74) | 0.44 | |
| Breast cancer | 3 | 0.10 | Fixed | 1.51 (0.55, 4.11) | 0.42 | |
| Colorectal cancer | 2 | - | Random | 1.97 (0.33, 11.90) | 0.46 | |
| (TT+CT) versus CC | Overall | 18 | <0.00001 | Random | 1.19 (0.88, 1.59) | 0.26 |
| Overall in HWE | 13 | <0.00001 | Random | 1.34 (0.97, 1.85) | 0.08 | |
| Caucasian | 11 | <0.00001 | Random | 1.15 (0.68, 1.93) | 0.61 | |
| Caucasian in HWE | 7 | <0.00001 | Random | 1.70 (0.89, 3.26) | 0.11 | |
| East Asian | 5 | 0.15 | Fixed | 1.01 (0.80, 1.27) | 0.96 | |
| Female* | 7 | 0.0004 | Random | 1.28 (0.76, 2.15) | 0.35 | |
| Female in HWE* | 6 | 0.0002 | Random | 1.41 (0.77, 2.57) | 0.26 | |
| Male (prostate cancer)** | 4 | <0.0001 | Random | 1.85 (1.04, 3.31) | 0.04 | |
| Male (prostate cancer) in HWE** |
3 | <0.0001 | Random | 1.75 (0.89, 3.47) | 0.11 | |
| Breast cancer | 3 | 0.22 | Fixed | 0.96 (0.76, 1.21) | 0.75 | |
| Colorectal cancer | 2 | 0.02 | Random | 0.25 (0.01, 5.99) | 0.39 |
OR, odds ratio; CI, confidence interval; HWE, Hardy-Weinberg equilibrium.
* Only female specific cancers were included in the female subgroup.
** All male patients were the patients with prostate cancer.